How much does HealthEquity have left to spend on buybacks?

$948.4 million remained authorized as of July 31, 2026. This suggests the original program authorization was approximately $1.056 billion, with $108.1 million deployed in Q2. At the current execution pace, the company has substantial room to continue repurchases into future periods.

What price did HealthEquity pay for the shares in Q2?

The company repurchased 1.2 million shares for $108.1 million, averaging $90.08 per share. This reflects execution during the second quarter ending July 31, 2026.

How do these buybacks affect HealthEquity's share count?

The buyback reduced diluted weighted-average shares from 87.7 million in Q2 FY2026 to 84.0 million in Q2 FY2027, a reduction of approximately 3.7 million shares year-over-year. This directly lifts earnings-per-share metrics even if net income remains flat.

Why is HealthEquity buying back shares now?

The company is generating strong operating cash flow ($233.7 million in H1 FY2027) and reported record Adjusted EBITDA margins of 48%. With increased profitability, the company is returning capital to shareholders through buybacks while maintaining long-term debt management.

Is this a one-time buyback or an ongoing program?

This is execution under an existing stock repurchase program. The company repurchased $108.1 million in Q2 and $231.1 million in the first half of FY2027, indicating ongoing repurchases. The remaining $948.4 million authorization suggests the program will continue into future periods.

How does HealthEquity fund these buybacks?

The company uses operating cash flow to fund repurchases. In H1 FY2027, operating activities generated $233.7 million in cash, while financing activities (including buybacks and debt payments) consumed $256.8 million. This demonstrates the company's strong cash generation supports both shareholder distributions and debt reduction.

HQY 8-K Filed 2026-08-27 New authorization

HealthEquity repurchased 1.2M shares for $108.1M in Q2 FY2027

Company executes open-market buyback with $948.4M remaining under existing authorization

Authorization$900M

Remaining$948M

MechanismNot specified

What the filing says

HealthEquity, Inc. (NASDAQ: HQY) repurchased 1.2 million shares of common stock for $108.1 million during the second quarter ended July 31, 2026, according to the company's earnings release filed as an 8-K on August 27, 2026. The repurchases were conducted under the company's existing stock repurchase program.

As of July 31, 2026, $948.4 million remained authorized for repurchase under the program, indicating an original authorization amount of approximately $1.056 billion. The execution mechanism was not explicitly specified in the filing, though open-market repurchases under Rule 10b-18 are the standard methodology for the company's program. The average price paid per share during Q2 was $90.08 ($108.1 million ÷ 1.2 million shares).

For the first half of fiscal 2027 (six months ended July 31, 2026), the company repurchased $231.1 million in common stock on a cash basis, reflecting an ongoing commitment to capital return as the company raised full-year guidance citing record Adjusted EBITDA margins of 48% and strong operational momentum.

execution

The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program. — HEALTHEQUITY, INC. 8-K filing · View on SEC EDGAR →

What this means

HealthEquity's $108.1 million Q2 repurchase demonstrates ongoing shareholder returns despite a capital-intensive business model. With $948.4 million remaining under authorization, the company has significant dry powder for continued buybacks. The $90.08 average price paid reflects execution discipline. The buyback reduced diluted share count from 87.7 million (prior-year Q2) to 84.0 million (current Q2), enhancing per-share metrics. Given the company's raised FY2027 guidance and strong cash flow generation ($233.7 million operating cash flow in H1 FY2027), the buyback is consistent with capital allocation toward both debt reduction and shareholder distributions.

Frequently asked questions

How much does HealthEquity have left to spend on buybacks?: $948.4 million remained authorized as of July 31, 2026. This suggests the original program authorization was approximately $1.056 billion, with $108.1 million deployed in Q2. At the current execution pace, the company has substantial room to continue repurchases into future periods.
What price did HealthEquity pay for the shares in Q2?: The company repurchased 1.2 million shares for $108.1 million, averaging $90.08 per share. This reflects execution during the second quarter ending July 31, 2026.
How do these buybacks affect HealthEquity's share count?: The buyback reduced diluted weighted-average shares from 87.7 million in Q2 FY2026 to 84.0 million in Q2 FY2027, a reduction of approximately 3.7 million shares year-over-year. This directly lifts earnings-per-share metrics even if net income remains flat.
Why is HealthEquity buying back shares now?: The company is generating strong operating cash flow ($233.7 million in H1 FY2027) and reported record Adjusted EBITDA margins of 48%. With increased profitability, the company is returning capital to shareholders through buybacks while maintaining long-term debt management.
Is this a one-time buyback or an ongoing program?: This is execution under an existing stock repurchase program. The company repurchased $108.1 million in Q2 and $231.1 million in the first half of FY2027, indicating ongoing repurchases. The remaining $948.4 million authorization suggests the program will continue into future periods.
How does HealthEquity fund these buybacks?: The company uses operating cash flow to fund repurchases. In H1 FY2027, operating activities generated $233.7 million in cash, while financing activities (including buybacks and debt payments) consumed $256.8 million. This demonstrates the company's strong cash generation supports both shareholder distributions and debt reduction.

execution healthcare-services rule-10b-18 share-count-reduction cash-return

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.